You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
Kedrion Biosc - Front Image


  1. 07-09-2018

    First half results 2018

    Consolidated turnover of Euro 278.3 million and adjusted gross margin of 39.0%

    read more 
  2. 17-07-2018

    Updated Bylaws

    Kedrion’s Extraordinary Meeting of Shareholders approves the amendment of the Company’s Bylaws

    read more 
  3. 28-05-2018

    Shareholders’ Agreement

    Sestant Internazionale, Sestant and FSI Investimenti sign a new Shareholders’ Agreement concerning Kedrion

    read more 
  4. 22-05-2018

    FY 2017 Results General Investor Call

    Friday 25 May 2018 – 09.00 GMT / 10.00 CET

    read more 
  5. 27-04-2018

    Annual General Meeting of Shareholders 2018

    Kedrion’s shareholders approve financial statements for fiscal year 2017, confirm board of directors

    read more 
  6. 29-03-2018

    Annual Results 2017

    Consolidated turnover of Euro 602.5 million and adjusted EBITDA of Euro 139.9 million, up 31.6%

    read more 
  7. 31-10-2017

    Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy

    Agreement covers complete INTERCEPT product line: platelets, plasma, and red blood cells

    read more 
  8. 25-08-2017

    Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

    The product is approved for post-exposure prophylaxis against rabies infection

    read more 
  9. 11-08-2017

    First half results 2017

    First half consolidated turnover of EUR 271.7 M and adjusted EBITDA increase by 29.0% compared to the same period in 2016, with a margin of 24.1%

    read more 


For more information please contact: